We selected the MYCN‐amplified neuroblastoma cell line SK‐N‐DZ, a representative of tumor entities that still defy current treatments and for which we and others have already reported a marked dependency on GPX4 (Lewerenz et al, 2018; Floros et al, 2021; Lu et al, 2021; Alborzinia et al, 2022), thus providing an ideal setting to interrogate the mechanisms underlying this hypersensitivity. This evidence concerns the gene GPX4 and neoplasm.